Table 1.
Baseline characteristics
| Characteristics | CT | BEV |
|---|---|---|
| N = 51 | N = 51 | |
| Age (years) | ||
| Median (min–max) | 80.1 (75.0–90.6) | 80.9 (75.2–88.3) |
| Sex | ||
| Male | 30 (58.8%) | 26 (51.0%) |
| Female | 21 (41.2%) | 25 (49.0%) |
| Primary localization | ||
| Right colon | 19 (37.3%) | 16 (31.4%) |
| Left colon | 18 (35.3%) | 21 (41.2%) |
| Rectum | 14 (27.5%) | 14 (27.5%) |
| Primary tumor resected | ||
| Yes | 30 (58.8%) | 31 (60.8%) |
| No | 21 (41.2%) | 20 (39.2%) |
| Chemotherapy regimen | ||
| LV5FU2 | 26 (51.0%) | 26 (51.0%) |
| FOLFOX | 14 (27.5%) | 9 (17.6%) |
| FOLFIRI | 9 (17.6%) | 16 (31.4%) |
| Not treated | 2 (3.9%) | 0 (0.0%) |
| Body Mass Index (kg/m2) | n = 50 | |
| <21 | 8 (16.0%) | 9 (17.6%) |
| ≥21 | 42 (84.0%) | 42 (82.4%) |
| Spitzer QoL | ||
| 0–7 | 16 (31.4%) | 15 (29.4%) |
| 8–10 | 35 (68.6%) | 36 (70.6%) |
| Biologics parameters | ||
| Alkaline phosphatases | n = 48 | |
| ≤2 LN | 37 (77.1%) | 42 (82.3%) |
| >2 LN | 11 (22.9%) | 9 (17.7%) |
| Hemoglobin (g/dl) | ||
| <10 (female), <11 (male) | 11 (21.6%) | 5 (9.8%) |
| ≥10 (female), ≥11 (male) | 40 (78.4%) | 46 (90.2%) |
| Albumin | n = 43 | n = 49 |
| ≤35 g/l | 20 (46.5%) | 17 (34.7%) |
| >35 g/l | 23 (53.5%) | 32 (65.3%) |
| Creatinine clearance | n = 48 | n = 50 |
| >45 ml/min | 37 (77.1%) | 36 (72.0%) |
| ≤45 ml/min | 11 (22.9%) | 14 (28.0%) |
| CEA | n = 49 | n = 47 |
| ≤2 LN | 35 (71.4%) | 40 (85.1%) |
| >2 LN | 14 (28.6%) | 7 (14.9%) |
| CA 19-9 | n = 47 | n = 48 |
| ≤2 LN | 19 (40.4%) | 29 (60.4%) |
| >2 LN | 28 (59.6%) | 19 (39.6%) |
LN, limit of normal; BMI, body mass index; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.